Crispr Therapeutics Viking Therapeutics: 2026 Stock Showdown
As biotech investors look to 2026, crispr therapeutics viking therapeutics presents two distinct paths: gene editing ...
Knowing when to switch from passive to active strategies can boost returns. This guide outlines practical signals, costs, and risk considerations.
27,240 articlesAs biotech investors look to 2026, crispr therapeutics viking therapeutics presents two distinct paths: gene editing ...
Tech shares rallied as semiconductors staged a comeback, lifting the Nasdaq Composite by 0.9%. This article explains ...
German carmakers posted steep Q2 declines in China, with losses up to 41%. The drop highlights ongoing headwinds from...
Analyst price targets SpaceX have sparked a heated debate among investors. This guide explains how targets are built,...
Investors face a 28% price return gap between XYLD and SPY as income-focused strategy meets growth potential. This re...
Two tech giants define growth storytelling in 2026: one leads cloud security, the other powers AI infrastructure. Thi...
Broadcom stock has stalled in a sideways move as AI infrastructure spending stays in focus. Analysts weigh a cautious...
A little-known dividend-focused ETF has boosted its quarterly payout 38% over three years, delivering steady income i...
Hims & Hers Health announces a major acquisition of Australian digital health firm Eucalyptus, valued at up to $1.15 ...
Bitcoin briefly dipped below $65,000 on Sunday as tariff headlines surged, but the crypto recovered Monday amid a bro...
Bitcoin edges toward the long-term holder cost basis as on-chain data flags growing risk of capitulation. Analysts wa...
Polkadot led a broad crypto rebound, climbing roughly 22% in 24 hours and reclaiming key levels as traders weigh supp...